Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience

Acne vulgaris is a globally prevalent dermatological condition associated with a substantial physical and psychological burden. This case series includes 10 patients with acne vulgaris who received treatment with clascoterone cream 1% from August 2023 to May 2024. Treatment with clascoterone cream 1% was effective and well tolerated regardless of acne severity, age, gender, and ethnicity. Clascoterone led to clinical improvement when used as monotherapy, as an adjunctive treatment in combination with other topical or systemic agents or laser therapy, and as maintenance therapy to prevent acne relapse. Moreover, clascoterone helped address other concerns in several patients, including hirsutism, hidradenitis suppurativa, retinoid-induced dermatitis, androgenetic alopecia, folliculitis, and laser‑induced acne flares. This recent real-world clinical experience supports the effectiveness, tolerability, and versatility of clascoterone cream 1% for patients with acne vulgaris across a variety of clinical and demographic characteristics.